Treatment Information

Back

Rectal Cancer treatment details. Chemotherapy, Radiation.

University of Erlangen, Erlangen, Germany.

Survival: monthsCountry:Germany
Toxiciy Grade:5City/State/Province:Erlangen
Treatments:Chemotherapy, RadiationHospital:University of Erlangen
Drugs:Journal:Link
Date:Jan 2007

Description:

Patients: This phase II trial involved 104 people with rectal adenocarcinoma. The median age was 61, ranging from 39 to 77 years. Seventy-three percent of the patients were men.

Treatment: Patients were given the chemotherapy drugs oxaliplatin and capecitabine before and after radiation and surgery.

Toxicity: Grade 5 toxic events (death) occurred in two patients; one due to septicemia and tumor progression, the other due to cardiac arrest. Diarrhea was the most common severe toxicity, 12% of patients had Grade 3 or 4 diarrhea. Other toxicities included leuokopenia, anemia, nausea/vomiting, dysuria, radiation dermatitis, and allergic reactions.

Results: The median survival time was not reported. Complete regression of the primary tumor was observed in 18 patients. A ‘pathological complete response’ was observed in 17 patients.

Support: Supported by grants from Hoffmann-La Roche and Sanofi-Aventis Pharma. Most of the authors have been a consultant, obtained research funds, and/or honoraria from them as well. Capecitabine is marketed by Hoffmann-La Roche as Xeloda, and oxaliplatin is marketed by Sanofi-Aventis as ELOXATIN (oxaliplatin injection).

Correspondence: Claus Rodel, M.D.





Back